Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer

KRAS and TP53 mutations, which are the most common genetic drivers of tumorigenesis, are still considered undruggable targets. Therefore, we analyzed these genetic aberrations in metastatic non-small cell lung cancer (NSCLC) for the development of potential therapeutics. One hundred eighty-five cons...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Wang, Yudong, Wang, Zhijie, Piha-Paul, Sarina, Janku, Filip, Subbiah, Vivek, Shi, Naiyi, Hess, Kenneth, Broaddus, Russell, Shan, Baoen, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Lu, Charles, Papadimitrakopoulou, Vali, Heymach, John, Meric-Bernstam, Funda, Fu, Siqing
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2018
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6161801/
https://ncbi.nlm.nih.gov/pubmed/30279957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25947
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items